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Abstract:  1 
Purpose: To evaluate the effectiveness of focal laser for treatment of diabetic macular edema (DME) 2 
performed by ophthalmology residents. 3 
Methods: Chart review of DME patients treated in a resident clinic with focal laser. Visual acuity (VA), 4 
OCT central subfield thickness (CST), and maximum subfield thickness (MST) at initial, 1 month, and 6 5 
month visits were recorded. 6 
Results: For 32 reviewed patients, average VA was 20/58 initially and 20/39 at 6 months (p=0.18). Mean 7 
CST was 311 µm initially and 305 µm at 6 months (p=0.09). Mean MST was 413 µm initially and 382 8 
µm at 6 months (p=0.007). Factors favoring success are: initial CST <400 µm, treatment of localized 9 
microaneurysms, and prior focal laser treatments.   10 
Conclusion: Focal laser performed by residents was effective in decreasing MST and maintained visual 11 
acuity.  Initial CST, localized microaneurysms and repeat focal treatment predicted improved outcomes. 12 
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 3 
Introduction 26 
  Diabetic macular edema (DME) is the most common cause of vision loss in diabetic retinopathy.1 27 
It is a prevalent disease, affecting 7% of people with diabetes.2 The mechanism for edema in diabetic 28 
retinopathy is due to abnormal vascular permeability.3 As in diabetic retinopathy, the greatest modifiable 29 
risk factor for the development of DME is hyperglycemia.4 DME is diagnosed by the presence of macular 30 
thickening observed via slit lamp biomicroscopy, stereoscopic fundus photos, or on optical coherence 31 
tomography (OCT) (figure 1). Other exam findings such as hard exudates in the presence of 32 
microaneurysms and blot hemorrhages within one disc diameter of the fovea have been utilized for 33 
diagnosis as well.4 Fluorescein angiography (FA) can also aid in diagnosis. It will show vascular leakage 34 
in the setting of edema, which frequently correlates well with OCT findings.5  35 
  Treatment of DME, with goals of immediate and sustained visual improvement and prevention of 36 
vision loss, has evolved through the years. The first available treatment option began in 1985 when the 37 
Early Treatment Diabetic Retinopathy Study established the effectiveness of laser photocoagulation for 38 
DME.6 Laser can be performed in focal pattern, targeting specific leaking microaneurysms, or in a grid 39 
pattern to target areas of more diffuse leakage.6 Our study concentrates on focal laser photocoagulation. 40 
  While laser was the only treatment option available for 20 years, there are now several other 41 
modalities available. The advent of intravitreal anti-vascular endothelial growth factor (VEGF) 42 
medications, beginning with pegaptanib in 2005 introduced a second treatment option, particularly useful 43 
for center-involving DME that is not amenable to laser treatment.7 Currently, ranibizumab, aflibercept, 44 
and the off-label use of bevacizumab, are available anti-VEGF agents, and these agents have dramatically 45 
changed the treatment of DME. The release of the Diabetic Retinopathy Clinical Research Network 46 
(DRCR.net) Protocol I data, demonstrated the role of intravitreal anti-VEGF agents in combination with 47 
focal/grid laser treatment.8    48 
  There are additional treatment options that may be utilized, particularly in refractory cases.  This 49 
includes intravitreal triamcinolone, which was superior to laser alone in pseudophakic eyes when studied 50 
in DRCR.net protocol I, as well as various other ocular steroid formulations.9 Lastly, DME that is 51 
 4 
associated with posterior hyaloid traction and/or epiretinal membrane may be amenable to improvement 52 
with pars plana vitrectomy.10  53 
  Given the multitude of treatment options and various treatment algorithms that have been studied, 54 
the decision for when focal laser is indicated is very practitioner-dependent and frequently based on 55 
personal experience. Our study analyzes focal laser treatments performed by multiple physicians in an 56 
inner-city population to identify patient selection factors and treatment parameters that correlated with 57 
successful outcomes. 58 
  59 
Methods 60 
  Patients with DME were selected from outpatient visits with multiple physicians at Parkland 61 
Memorial Hospital (Dallas, TX). The study was conducted in accordance with the World Medical 62 
Association Declaration of Helsinki. 63 
  The study consisted of 32 patients, 24 (75%) of which were male. The population was 64 
predominantly Hispanic (59.4%), and the average age was 65 years old. Average hemoglobin A1c was 65 
8.3%. See table 1 for additional demographic characteristics. 66 
  Patient selection for receiving focal laser treatment was physician dependent, and these selection 67 
factors were analyzed in the study. Exclusion criteria included macula edema not secondary to diabetic 68 
retinopathy (e.g. retinal vein occlusion, Irvine-Gass Syndrome, uveitic macular edema), lack of return for 69 
the 1 month follow-up appointment, or if pre-treatment or post-treatment OCT’s (Heidelberg Spectralis) 70 
were not available. 71 
  For each selected patient, laser treatment was performed with an Iridex 532 nm green laser 72 
through a slit-lamp delivery system in single spots without pattern scanning. The lens used for all 73 
treatments was a Volk Area Centralis contact lens. Treatment parameters including laser power and 74 
duration settings, spot size, number of shots, and pattern of treatment were analyzed. 75 
  Patients returned for 1-month follow-up, with the primary outcomes examined at that visit 76 
including visual acuity change, OCT central subfield thickness (CST) change, and maximal subfield 77 
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thickness (MST) change as compared to pre-treatment values. MST was analyzed because the goal of 78 
many focal laser treatments was to target a non-central area of leakage in order to prevent future central 79 
involvement. 80 
 81 
Results 82 
  Visual acuity was recorded on logMAR scale, with a pre-treatment average visual acuity of 0.42 83 
(corresponding to 20/52) and 1-month post treatment average visual acuity of 0.34 (corresponding to 84 
20/44). The average CST was 322.26 µm pre-treatment and 325.81 µm post-treatment, while the average 85 
MST did improve marginally from 418.29 µm to 407.74 µm. Average laser parameters used were 86 
96.78mW power, 0.1 second duration, 91.38 µm spot size, and shot count of 4.43. 87 
  When comparing patients with less than 400 µm CST (n = 57) pre-treatment to patients with 88 
greater than 400 µm (n = 10), there was a statistically significant (p = 0.0001) difference in CST change 89 
and MST change at 1 month, favoring those patients with thinner pre-treatment CST. This is attributable 90 
to the fact that in eyes with CST greater than 400 µm, significant amount of the leakage was centrally 91 
located and was not amenable to focal laser. This OCT improvement did not, however, correlate with 92 
statistically significant visual acuity improvement advantage for those with less than 400 µm pre-93 
treatment.  See Table 2 for detailed study results. 94 
 Conclusions 95 
For patients who had less than 5 microaneurysms targeted with laser treatment, there was a 96 
statistically significant difference in visual acuity, CST, and MST outcomes at 1 month as compared to 97 
other targets of treatment. In those patients with fewer microaneurysms targeted, the source of leakage 98 
was more focal and therefore responded better to laser treatment. 99 
  Due to limited resources at our county hospital, FA was only able to be obtained prior to laser 100 
treatment in 1/3 of the cases where the source of leakage was uncertain (i.e. many candidate 101 
microaneurysms), but there was no significant relationship found between visual acuity or OCT outcomes 102 
at 1 month whether the patient had an FA conducted prior to treatment or not. 103 
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  Laser parameters were evaluated, and patients were found to have worse outcomes when power 104 
settings outside the range of 80-100 mW were utilized, with worse visual acuity, CST, and MST 105 
outcomes at 1 month (p = 0.039, 0.022, and 0.014, respectively), as compared to those treatments 106 
conducted within the 80-100 mW range. This is likely due to laser power of less than 80 mW being 107 
inadequate to sufficiently coagulate microaneurysms or induce significant local photo-chemical changes, 108 
and power greater than 100 mW likely inducing more local inflammatory changes which temporarily 109 
worsened the swelling at 1 month.   110 
  Visual acuity outcomes at 1 month were worse for patients who had previous focal or grid laser 111 
treatment prior to this study as compared to those who had no prior laser (p = 0.07). 112 
  There was no significant correlation found between hemoglobin A1c level and visual acuity, 113 
CST, or MST outcomes at 1 month follow up. There was also no correlation found between number of 114 
intravitreal bevacizumab (Avastin) injections received in the previous 6 months and post-laser 115 
outcomes.     116 
  Overall, focal laser photocoagulation for DME in an inner-city county hospital population 117 
improved visual acuity and stabilized macular swelling at 1 month post-treatment. Predictive factors for 118 
favorable focal laser outcomes included pre-treatment CST of less than 400 µm, treatment targeting fewer 119 
than 5 microaneurysms in a focal area of swelling, and using laser parameters of power between 80 mW 120 
and 100 mW. Prior fluorescein angiography, prior macular laser treatments, and hemoglobin A1c 121 
percentage did not correlate with improvement at 1 month. 122 
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Figure legends 156 
Figure 1 - OCT images from a patient who received focal grid laser treatment.  1A - pre-treatment image 157 
with temporal macular edema.  1B - 1 month post-treatment image with improved temporal macular 158 
edema.  159 
 160 
